Modified Gamma Delta T Cells for Cancer Therapy
Summary
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
What changed
USPTO published patent application US20260097077A1 covering compositions and methods for cancer therapy using gamma delta T cells engineered to inhibit XBP1 gene expression or protein activity. The modified cells exhibit superior antitumor activity in endoplasmic reticulum stress environments compared to unmodified gamma delta T cells. The application includes claims to treatment methods, compositions comprising the modified cells, and pharmaceutical formulations.
For pharmaceutical and biotech companies developing T cell-based cancer immunotherapies, this patent represents potential freedom-to-operate considerations. Competitors working with gamma delta T cells or XBP1 inhibitors in oncology may need to evaluate design-around options or seek licenses. The broad claims to ER stress-targeting approaches could affect multiple immunotherapy development programs.
What to do next
- Monitor for patent prosecution updates
- Review Freedom to Operate for related therapeutic applications
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for cancer therapy using modified gamma delta T cells
Application US20260097077A1 Kind: A1 Apr 09, 2026
Inventors
Minkyung SONG, Hocheol SHIN, Ji Yun PARK
Abstract
The present invention relates to a method for treating cancer, comprising administering a composition comprising γδ T cells treated with an inhibitor of XBP1 gene expression or an inhibitor of XBP1 protein expression or activity. The γδ T cells, in which the XBP1 gene is deficient or the XBP1 protein activity is inhibited, exhibit enhanced antitumor activity in a tumor microenvironment characterized by endoplasmic reticulum (ER) stress, as compared to unmodified γδ T cells. Accordingly, the modified γδ T cells are effective for use in cancer treatment.
CPC Classifications
A61K 35/17 A61P 35/00 C12N 9/226 C12N 15/11 C12N 15/86 C12N 15/907 C12N 2310/20 C12N 2740/15043
Filing Date
2025-09-04
Application No.
19318631
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.